RCT: Reloxaliase vs. placebo in enteric hyperoxaluria.
9 May, 2022 | 01:30h | UTCRandomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria – NEJM Evidence
Commentary on Twitter
Patients with enteric hyperoxaluria received reloxaliase, an enzyme that degrades oxalate in the GI tract, or placebo with food for 4 weeks. There was a greater reduction in urinary oxalate excretion with reloxaliase. https://t.co/x7m12QHyWX#NephTwitter #UroSoMe #ClinicalTrials pic.twitter.com/rzCpd6YfLM
— NEJM Evidence (@NEJMEvidence) May 6, 2022